VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference
VYNE Therapeutics Inc. announced that CEO David Domzalski will present at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 2:10 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VYNE Therapeutics Inc. announced that CEO David Domzalski will present at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 2:10 PM ET. The presentation will be in a fireside chat format, providing insights into the company's innovative therapies in dermatology, including AMZEEQ® and ZILXI®, both FDA-approved minocycline products. For those interested, the webcast link is here. VYNE aims to enhance the lives of patients through proprietary therapies.
Details
News Market Reaction – VYNE
The recorded move for VYNE in the trading session of this news was -2.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Cowen 41st Annual Health Care Conference.
Presentation details can be found below.
| Day: | Tuesday, March 2, 2021 |
| Time: | 2:10pm Eastern Time |
| Format: | Fireside chat |
| Webcast Link: | https://wsw.com/webcast/cowen81/vyne/1982826 |
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam,
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
CONTACT:
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com
Andrew Saik
Chief Financial Officer
VYNE Therapeutics
908-731-6180
Andrew.Saik@vynetx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.